INTERVENTION 1:	Intervention	0
Stage 1 Clinical Management	Intervention	1
The group will receive clinical management treatment only each session.	Intervention	2
group	CHEBI:24433	4-9
Clinical Management: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.	Intervention	3
group	CHEBI:24433	233-238
group	CHEBI:24433	254-259
Following are major elements:	Intervention	4
Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible.	Intervention	5
cancer	DOID:162	101-107
cancer	DOID:162	160-166
depression	HP:0000716	112-122
depression	HP:0000716	171-181
drug	CHEBI:23888	150-154
drug	CHEBI:23888	267-271
INTERVENTION 2:	Intervention	6
Stage 1 CBT	Intervention	7
The experimental group will receive CBT each session.	Intervention	8
group	CHEBI:24433	17-22
CBT and clinical management: The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.	Intervention	9
week	UO:0000034	116-120
month	UO:0000035	134-139
month	UO:0000035	156-161
month	UO:0000035	186-191
second	UO:0000010	169-175
second	UO:0000010	307-313
response to stress	GO:0006950	534-552
application	CHEBI:33232,BAO:0110001	554-565
efficacy	BAO:0000656	633-641
Inclusion Criteria:	Eligibility	0
Age: 20-65 years;	Eligibility	1
age	PATO:0000011	0-3
Pathologically diagnosed breast cancer patients, with the diagnosis from at least 2 comprehensive clinical attending physicians, in line with clinical diagnosis of breast cancer;	Eligibility	2
breast cancer	DOID:1612	25-38
breast cancer	DOID:1612	164-177
A week after breast cancer surgery;	Eligibility	3
week	UO:0000034	2-6
breast cancer	DOID:1612	13-26
surgery	OAE:0000067	27-34
With complaints and symptoms of depression or anxiety	Eligibility	4
depression	HP:0000716	32-42
anxiety	HP:0000739,DOID:2030	46-53
HAMD-17  8 points or / and HAMA  8 points;	Eligibility	5
Have some reading comprehension skills (could complete the self-rating scale independently or with others' help);	Eligibility	6
Informed consent	Eligibility	7
Exclusion Criteria:	Eligibility	8
Previous diagnosis of mental disorder or Bipolar Disorder; alcohol and drug abusing history;	Eligibility	9
disorder	OGMS:0000045	29-37
disorder	OGMS:0000045	49-57
bipolar disorder	DOID:3312	41-57
alcohol	CHEBI:16236	59-66
drug	CHEBI:23888	71-75
history	BFO:0000182	84-91
Use antidepressants, antipsychotics or accept any form of psychological treatment, or participation in other clinical trials in the last month	Eligibility	10
month	UO:0000035	137-142
Patients with cardiovascular disease, liver and kidney dysfunction and other serious diseases;	Eligibility	11
disease	DOID:4,OGMS:0000031	29-36
disease	DOID:4,OGMS:0000031	85-92
liver	UBERON:0002107	38-43
kidney	UBERON:0002113	48-54
Hearing, visual or understanding impairment;	Eligibility	12
Severe depression, suicidal tendencies;	Eligibility	13
severe	HP:0012828	0-6
depression	HP:0000716	7-17
Can not or will not comply with clinical treatment programs based on the physicians' judgment	Eligibility	14
Exit criteria:	Eligibility	15
Persons with poor compliance during the trial period;	Eligibility	16
Persons whose depression increased during the trial period, has serious suicidal tendencies and requires urgent intervention;	Eligibility	17
depression	HP:0000716	14-24
Persons who are believed have other circumstances and should be suspended by Physicians	Eligibility	18
Outcome Measurement:	Results	0
Hamilton Depression Rating Scale (HAMD-17)	Results	1
depression	HP:0000716	9-19
The scale(HAMD-17) is used to assessed the depression symptoms of patients.	Results	2
depression	HP:0000716	43-53
The scale range is 0-53.Higher value represents a worse outcome.	Results	3
range	LABO:0000114	10-15
The scale was assessed at baseline,2 week,4 week,8 week,12 week,16 week,24 week	Results	4
week	UO:0000034	37-41
week	UO:0000034	44-48
week	UO:0000034	51-55
week	UO:0000034	59-63
week	UO:0000034	67-71
week	UO:0000034	75-79
Time frame: baseline,2 w,4 w,8 w,12 w,16 w,24 w	Results	5
time	PATO:0000165	0-4
Results 1:	Results	6
Arm/Group Title: Stage 1 Clinical Management	Results	7
Arm/Group Description: The group will receive clinical management treatment only each session.	Results	8
group	CHEBI:24433	4-9
group	CHEBI:24433	27-32
Clinical Management: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.	Results	9
group	CHEBI:24433	233-238
group	CHEBI:24433	254-259
Following are major elements:	Results	10
Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible.	Results	11
cancer	DOID:162	101-107
cancer	DOID:162	160-166
depression	HP:0000716	112-122
depression	HP:0000716	171-181
drug	CHEBI:23888	150-154
drug	CHEBI:23888	267-271
Overall Number of Participants Analyzed: 98	Results	12
Mean (Standard Deviation)	Results	13
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: units on a scale  baseline: 11.52         (3.789)	Results	14
2W: 10.23         (3.207)	Results	15
4W: 9.80         (3.056)	Results	16
8W: 8.71         (3.601)	Results	17
12W: 8.01         (3.200)	Results	18
16W: 7.42         (3.019)	Results	19
24W: 7.01         (3.317)	Results	20
Results 2:	Results	21
Arm/Group Title: Stage 1 CBT	Results	22
Arm/Group Description: The experimental group will receive CBT each session.	Results	23
group	CHEBI:24433	4-9
group	CHEBI:24433	40-45
CBT and clinical management: The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.	Results	24
week	UO:0000034	116-120
month	UO:0000035	134-139
month	UO:0000035	156-161
month	UO:0000035	186-191
second	UO:0000010	169-175
second	UO:0000010	307-313
response to stress	GO:0006950	534-552
application	CHEBI:33232,BAO:0110001	554-565
efficacy	BAO:0000656	633-641
Overall Number of Participants Analyzed: 98	Results	25
Mean (Standard Deviation)	Results	26
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: units on a scale  baseline: 13.31         (5.090)	Results	27
2W: 11.72         (4.976)	Results	28
4W: 9.72         (4.835)	Results	29
8W: 7.80         (4.440)	Results	30
12W: 5.71         (3.979)	Results	31
16W: 5.13         (4.108)	Results	32
24W: 4.45         (3.875)	Results	33
Adverse Events 1:	Adverse Events	0
Total: 0/98 (0.00%)	Adverse Events	1
Adverse Events 2:	Adverse Events	2
Total: 0/98 (0.00%)	Adverse Events	3
